Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide Extension Study in Polycystic Liver Disease
NCT00771888Phase 3Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Apr 2008
- Primary completion
- Oct 2008
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of lanreotide in Polycystic liver disease (PLD), sponsored by Radboud University Medical Center. Primary endpoint: Liver volume reduction at 24 weeks. Status: unknown.
02
Drugs
lanreotide
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NCT00771888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771888.